Wiad Lek. 2026;79(4):755-762. doi: 10.36740/WLek/216923.
ABSTRACT
OBJECTIVE: Aim: To investigate the clinical and laboratory features of breast cancer with the progression of the tumour process, after complex treatment, depending on the stage of the disease and the molecular type of the tumour, and to determine the prognostic value of each factor.
PATIENTS AND METHODS: Materials and Methods: A retrospective analysis of 701 outpatient records of patients with breast cancer in the long term, after complex treatment, was performed. Patients, depending on the presence of verified breast cancer progression, were divided into two groups – 472 (67.3%) patients ‘without tumour progression’ and 229 (32.7%) patients ‘with tumour progression’. The informativeness of the studied indicators and diagnostic coefficients was determined using the Kullback method. The results were statistically processed using Microsoft Excel spreadsheets and the PAST statistical processing software package.
RESULTS: Results: Breast cancer progression occurs more often at stage III of the disease, in Lum.-B, Her/2new+, and Triple-negative tumour types. The progression of breast cancer is characterized by a relatively more extended history of the disease, a larger size of the primary tumour, and a higher percentage of comorbidities. The study of the informativeness of the studied indicators and diagnostic coefficients made it possible to form a table of prognosis of possible progression of breast cancer after complex treatment.
CONCLUSION: Conclusions: The prognostic model of breast cancer progression enables to obtain the prediction of the absence of tumour progression, uncertain prognosis, and the appearance of the latter, with the sensitivity (Se=75%) and specificity (Sp=75%) of this model.
PMID:42139613 | DOI:10.36740/WLek/216923
